French Startup Builds AI-Powered Radiology Viewer Used by Moffitt Cancer Center

A French-American startup is bringing AI-powered radiology to one of the nation’s leading cancer research hubs. Raidium, which operates out of Paris and Silicon Valley, has officially launched its AI-native imaging platform at Moffitt Cancer Center, marking a significant step in the company’s U.S. expansion.

The platform, Raidium Read, was deployed to replace Moffitt’s older radiomics applications. It is now being used for clinical trials and research, with FDA 510(k) clearance anticipated before the end of the year. The technology is designed to help radiologists and oncologists analyze medical images more quickly and accurately, potentially improving detection and treatment planning for cancer patients.

By integrating directly into Moffitt’s existing workflow, Raidium Read aims to streamline how imaging data is processed and interpreted. The startup’s approach relies on deep learning models trained on vast datasets, enabling the software to identify subtle patterns that might be missed by the human eye. This kind of AI-assisted diagnostics is becoming increasingly critical as the volume of medical imaging grows and the demand for precision medicine intensifies.

For Raidium, landing a partnership with a top-tier institution like Moffitt is a major validation. The cancer center, based in Tampa, Florida, is renowned for its research and clinical care. By adopting Raidium’s platform, Moffitt gains access to cutting-edge tools that could accelerate the pace of oncology research and improve patient outcomes.

The startup’s dual presence in both tech hubs gives it a unique vantage point, blending European research rigor with Silicon Valley’s speed of execution. With regulatory approval on the horizon, Raidium is positioning itself as a serious contender in the AI medical imaging market, a space that is rapidly becoming crowded but still has room for specialized, oncology-focused solutions.